Format

Send to

Choose Destination
Haematologica. 2019 Apr 19. pii: haematol.2019.219683. doi: 10.3324/haematol.2019.219683. [Epub ahead of print]

Pretreatment CD38-positive regulatory T-cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.

Author information

1
Kameda Medical Center akihiro_kitadate@yahoo.co.jp.
2
Kameda Medical Center.

KEYWORDS:

CD38 antibody; Multiple Myeloma; Regulatory T cell; daratumumab

PMID:
31004032
DOI:
10.3324/haematol.2019.219683
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center